Related Experiment Video

Updated: May 13, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance

Geoffrey T Gibney1, Keiran S M Smalley

  • 1Departments of 1Cutaneous Oncology and 2Molecular Oncology, H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, USA.

Cancer Discovery
|March 12, 2013
PubMed

Insights

Loss of the neurofibromin (NF1) tumor suppressor drives melanoma development and BRAF inhibitor resistance. These findings suggest new therapeutic strategies for BRAF-mutant/NF1-deficient melanomas.

Area of Science:

  • Oncology
  • Cancer Biology
  • Melanoma Research

Background:

  • Neurofibromin (NF1) is a tumor suppressor.
  • Loss of NF1 function is implicated in various cancers.
  • Cutaneous melanoma is a significant public health concern.

Purpose of the Study:

  • To investigate the role of NF1 loss in melanoma initiation and progression.
  • To identify mechanisms by which NF1 loss contributes to BRAF inhibitor resistance.
  • To explore novel therapeutic strategies for NF1-deficient melanomas.

Main Methods:

  • Development of a novel transgenic mouse model for melanoma.
  • Utilizing high-throughput short hairpin RNA (shRNA) screening.
  • Analysis of oncogene-induced senescence and drug resistance pathways.

Main Results:

  • Mutant BRAF cooperates with NF1 loss to drive melanoma development by abrogating oncogene-induced senescence.
  • NF1 loss mediates acquired and intrinsic resistance to BRAF inhibitors.
  • NF1 deficiency promotes melanoma growth and progression.

Conclusions:

  • NF1 loss is a critical factor in melanoma pathogenesis.
  • Targeting NF1-deficient melanomas may overcome therapeutic resistance.
  • These findings offer new avenues for treating BRAF-mutant/NF1-deficient melanoma patients.

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...